Clinical Trials | January 01, 2026
SOFIE Biosciences doses first patient in Phase 3 trial of novel cancer imaging agent
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The study will run across 18 sites and enroll roughly 200 patients over 24 months
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Applications include detailed scientific rationale and supporting clinical evidence
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The study met its primary endpoint with flying colors
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Harbour BioMed brings advanced antibody discovery platforms to the table
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
The primary goal of the collaboration is joint research into trending and next-generation molecules
Subscribe To Our Newsletter & Stay Updated
